Actively Recruiting
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Led by Stanford University · Updated on 2026-02-10
24
Participants Needed
1
Research Sites
225 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.
CONDITIONS
Official Title
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with locoregionally advanced EBV positive nasopharyngeal carcinoma (T3-4, any N or any T, N1-3, no distant metastasis) per AJCC v8
- No prior therapy for nasopharyngeal carcinoma
- Expected life expectancy of at least 3 months
- Women of childbearing potential and sexually active men agree to use effective birth control during treatment and for 4 months after last dose of toripalimab
- ECOG performance status of 0, 1, or 2
- At least 18 years old
- Adequate bone marrow function within 21 days before treatment: ANC ≥ 1,500 cells/mm3, platelets ≥ 100,000 cells/mm3, hemoglobin ≥ 8.0 g/dl
- Adequate liver function within 21 days before treatment: total bilirubin ≤ 1.5 x institutional upper limit, AST and ALT ≤ 1.5 x institutional upper limit
- Adequate kidney function within 21 days before treatment: serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 50 ml/min
- Negative pregnancy test within 14 days before treatment for women of childbearing potential
- Ability and willingness to sign informed consent
You will not qualify if you...
- Prior systemic anticancer treatment for nasopharyngeal carcinoma
- Prior radiation to head and neck region requiring overlapping fields
- Concurrent use of any anticancer treatment, standard, alternative, or investigational
- History of allergic reactions to any study agents
- Autoimmune disease or organ transplant increasing risk of immune checkpoint inhibition
- Pregnant or breastfeeding
- Severe active co-morbidities including major medical or psychiatric illness interfering with treatment or follow-up
- Unstable angina or uncontrolled congestive heart failure within past 6 months
- Myocardial infarction within last 6 months
- Current acute bacterial or fungal infection requiring IV antibiotics (patients on oral antibiotics with controlled infection may participate)
- COPD exacerbation or respiratory illness requiring hospitalization or precluding therapy within 30 days before treatment
- AIDS diagnosis based on current CDC definition
- Hearing loss primarily sensorineural requiring aid or intervention interfering with daily activities (tumor-related conductive hearing loss allowed)
- Peripheral sensory neuropathy grade 2 or higher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University
Palo Alto, California, United States, 94304
Actively Recruiting
Research Team
E
Elizabeth Winters
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here